Introduction to Milliman's Healthcare Inflation ETFs
Milliman, Inc., a leading provider of actuarial and risk management services, has introduced two innovative active exchange-traded funds (ETFs) aimed at addressing one of the most intractable components of U.S. inflation: healthcare costs. The Milliman Healthcare Inflation Guard ETF (MHIG) and the Milliman Healthcare Inflation Plus ETF (MHIP) began trading this week on NYSE Arca, advised by Milliman Financial Risk Management LLC (Milliman FRM).[1]
MHIG is designed to generate returns that closely match the U.S. healthcare cost inflation rate over time, benchmarked against Milliman's proprietary Health Trend Guidelines (HTGs). In contrast, MHIP targets returns that exceed this rate, providing an active management approach to outpace rising medical expenses.[1] This launch comes at a critical juncture, as healthcare inflation continues to outstrip general CPI, exerting pressure on consumers, employers, and policymakers alike.
Context of U.S. Healthcare Inflation Trends
Healthcare costs have long been a structural challenge in the U.S. economy. According to Milliman's HTGs, which are widely used by insurers and plan sponsors, healthcare cost trends for 2025 are projected to remain elevated, driven by factors such as prescription drug prices, labor shortages in medical staffing, and advanced treatments like gene therapies. While overall CPI inflation has moderated in recent years, healthcare components— including medical care services and pharmaceuticals—have consistently trended higher, often by 2-4 percentage points above the core rate.
The introduction of MHIG and MHIP directly responds to this dynamic. As Milliman notes, these ETFs provide "tools to meet the rising cost of U.S. healthcare, a key financial risk that impacts all Americans."[1] For institutional investors and retirement plans, this represents a targeted hedge against a cost category that erodes purchasing power more acutely than headline inflation figures suggest.
Impact on Equities: Sector Rotation and Small-Cap Resilience
The debut of these ETFs coincides with mixed signals in healthcare equities. The Invesco S&P SmallCap Health Care ETF (PSCH) recently posted a massive loss, yet analysts project a strong rebound in 2026 Q1, citing the sector's inherent resilience amid biotech innovations and demographic tailwinds.[2] Small-cap healthcare firms, often focused on niche therapies and devices, stand to benefit from inflation-hedging demand, as investors seek exposure uncorrelated with mega-cap pharma.
Conversely, the Invesco Healthcare ETF (PTH), which tracks a broader index, reported a $995 million loss, with analysts maintaining a neutral stance on its 2026 Q1 outlook due to a challenging market environment.[3] This divergence highlights a bifurcation: defensive large-cap healthcare stocks may face headwinds from pricing pressures and regulatory scrutiny, while nimbler small-caps could thrive. Milliman's ETFs, by focusing on inflation metrics rather than equity baskets, offer a purer play on cost trends, potentially drawing capital from traditional healthcare equity funds and fostering sector rotation.
Broader equity markets could see a mild positive lift. Healthcare inflation's persistence reinforces the case for value-oriented sectors, as higher costs squeeze consumer discretionary spending but bolster defensive plays like health insurers and providers. With the S&P 500's healthcare sector weighting around 12-13%, any hedging inflows could support index stability, particularly if general inflation fears resurface.
Bonds and Fixed Income Implications
For bond markets, healthcare inflation ETFs like MHIG and MHIP introduce a novel real-asset proxy. Traditional Treasury Inflation-Protected Securities (TIPS) capture headline CPI, which underweights healthcare relative to its household budget share (approximately 8-10%). These new ETFs fill that gap, potentially competing with short-duration TIPS or I-Bonds for inflation-sensitive portfolios.
Rising healthcare costs amplify fiscal pressures on Medicare and Medicaid, which account for over 25% of federal healthcare spending. If MHIP and MHIG gain traction, they could signal investor expectations of sustained 4-6% annual healthcare inflation, pressuring longer-term yields upward. The 10-year Treasury yield, recently hovering near 4.2%, might face renewed volatility if fund flows highlight embedded inflation risks overlooked by headline data.
Corporate bonds in healthcare—issued by hospitals, pharma giants, and device makers—could benefit from hedging clarity. Issuers facing cost inflation may find it easier to price debt if investors can directly hedge those risks, narrowing credit spreads by 10-20 basis points in the sector.
Currency and Global Macro Ramifications
On the currency front, U.S. healthcare inflation underscores dollar strength themes. As a uniquely American challenge—other developed markets have more socialized systems—these costs contribute to the USD's safe-haven status. Persistent inflation here bolsters the case for higher-for-longer Fed rates, supporting the dollar against peers like the euro and yen.
The DXY index, up modestly year-to-date, could extend gains if Milliman's ETFs highlight U.S.-specific inflationary rigidities. Emerging market currencies, vulnerable to dollar strength, may depreciate further, as higher U.S. healthcare spending diverts global capital from riskier assets.
Investor Sentiment and Allocation Shifts
Sentiment around these launches is cautiously optimistic. The active management wrapper appeals to defined contribution plans and RIAs seeking alternatives to passive CPI trackers. With assets under management in inflation ETFs surpassing $50 billion industry-wide, MHIG and MHIP could capture 1-2% market share within months, per analyst estimates.
Retail investor sentiment, gauged by social media buzz and app downloads, shows growing awareness of healthcare as an inflation wildcard. This aligns with surveys indicating 60% of Americans worry about medical costs outpacing wages. The ETFs' focus on "plus" returns via MHIP taps into bullish undercurrents, positioning them as growth-oriented hedges rather than mere defenders.
Institutional sentiment remains data-driven. Pension funds, with actuarial assumptions tied to HTGs, may allocate 0.5-1% of portfolios, enhancing overall market stability. However, if healthcare inflation moderates unexpectedly—say, via drug price negotiations under the Inflation Reduction Act—performance could lag, tempering enthusiasm.
Comparative Analysis: MHIG vs. MHIP and Peers
MHIG: Tracks HTG inflation rate (target: equivalent returns). Ideal for conservative hedging in retirement portfolios.
MHIP: Seeks to exceed HTG (active outperformance via derivatives, equities). Suited for total return seekers.
Vs. PSCH: Equity-focused small-cap exposure with volatility; analysts eye 2026 Q1 upswing despite losses.[2]
Vs. PTH: Broader healthcare equities; neutral outlook amid $995M AUM drop.[3]
This lineup diversifies options, reducing concentration risk in pure equity bets.
Broader Macroeconomic Ties to Fed Policy
Healthcare inflation influences Fed dot plots indirectly. Core PCE, the central bank's preferred gauge, strips food and energy but retains medical services, which comprise ~20% of the basket. Elevated trends here delayed rate cuts in 2025; new ETFs amplify visibility, potentially anchoring expectations for fewer 2026 easings.
Assuming 3.5% core PCE by Q2 2026, healthcare's 1-2 point premium justifies a terminal rate near 3.75-4%. This setup favors carry trades in short-dated bonds while capping equity multiples.
Risks and Forward Outlook
Risks include tracking error from active strategies and HTG revisions. If drug pricing reforms accelerate, inflation could undershoot, hurting MHIP. Regulatory changes, like expanded Medicare Advantage, add uncertainty.
Yet, demographics—aging boomers driving 10% annual Medicare growth—support long-term tailwinds. Analysts' PSCH optimism reinforces sector durability.[2] With markets pricing soft landing probabilities at 70%, these ETFs enhance portfolio insurance without sacrificing yield.
In summary, Milliman's launch marks a milestone in inflation product innovation. By isolating healthcare—a stealth CPI driver—these funds empower investors to navigate rising costs proactively. Equities gain defensive depth, bonds find yield anchors, currencies reflect policy resilience, and sentiment tilts toward structured optimism. As adoption builds, expect ripple effects across asset classes, underscoring healthcare's enduring market influence.
